Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen

NCT02274259 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Central Retinal Vein Occlusion

Interventions

DRUG: Aflibercept
DRUG: Ranibizumab

Sponsor

Anders Kvanta